August 13, 2018 10:00 AM EDTUpdated 10:44 AM

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

The bare-knuckle brawl between Vertex’s executive crew and NICE has now extended to its new cystic fibrosis combo Symkevi — matching tezacaftor and ivacaftor. …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

This article is available only to Premium subscribers

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Ver­tex’s fight club rule: Block new treat­ments to cys­tic fi­bro­sis pa­tients un­til Orkam­bi is re­im­bursed prop­er­ly

This article is available only to Premium subscribers

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Vertex’s fight club rule: Block new treatments to cystic fibrosis patients until Orkambi is reimbursed properly

The election is Tuesday. What’s at stake for the pharma industry?

'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks